Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 25, 24 | 0.00 Decreased by N/A% | -1.98 Increased by +100.00% |
| Nov 29, 23 | 0.00 Increased by +100.00% | - |
| Aug 29, 23 | 0.00 Decreased by -100.00% | -4.09 Increased by +100.00% |
| Apr 28, 23 | -0.08 Increased by +69.23% | -1.76 Increased by +95.45% |
| Nov 30, 22 | 0.00 Increased by +100.00% | - |
| Aug 25, 22 | -0.10 Increased by +24.13% | -2.78 Increased by +96.40% |
| Apr 26, 22 | 0.05 Increased by +124.22% | -2.55 Increased by +101.96% |
| Aug 24, 21 | -0.26 Decreased by -161.90% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 144.00 K Decreased by -90.86% | -20.89 M Decreased by -67.07% | Decreased by -14.50 K% Decreased by -1.73 K% |
| Mar 31, 24 | 144.00 K Increased by +N/A% | -20.89 M Decreased by N/A% | Decreased by -14.50 K% - |
| Sep 30, 23 | 90.00 K Decreased by -97.90% | -20.35 M Decreased by -84.88% | Decreased by -22.61 K% Decreased by -8.72 K% |
| Jun 30, 23 | 3.15 M Decreased by -55.19% | -25.00 M Increased by +11.78% | Decreased by -793.81% Decreased by -96.88% |
| Mar 31, 23 | 1.57 M Increased by +N/A% | -12.50 M Decreased by N/A% | Decreased by -793.78% - |
| Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Sep 30, 22 | 4.29 M Increased by +N/A% | -11.01 M Decreased by N/A% | Decreased by -256.32% - |
| Jun 30, 22 | 7.03 M Increased by +N/A% | -28.34 M Decreased by N/A% | Decreased by -403.19% - |